International Journal of Heart Failure

The Korean Society of Heart Failure (대한심부전학회)
권호 표지
DOI QR코드

DOI QR Code

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF

  • Giuseppe M.C. Rosano (Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome) ;
  • Cristiana Vitale (St George's University Medical School of London) ;
  • Ilaria Spoletini (IRCCS San Raffaele)
  • Received : 2023.10.30
  • Accepted : 2024.03.08
  • Published : 2024.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent over half of heart failure cases but lack proven effective therapies beyond sodium-glucose cotransporter 2 inhibitor and diuretics. HFmrEF and HFpEF are heterogeneous conditions requiring precision phenotyping to enable tailored therapies. This review covers concepts on precision medicine approaches for HFmrEF and HFpEF. Areas discussed include HFmrEF mechanisms, anti-inflammatory and antifibrotic treatments for obesity-related HFpEF, If inhibition for HFpEF with atrial fibrillation, and mineralocorticoid receptor antagonism for chronic kidney disease-HFpEF. Incorporating precision phenotyping and matched interventions in HFmrEF and HFpEF trials will further advance therapy compared to blanket approaches.

Keywords

Acknowledgement

This study was supported by the Italian Ministry of Health (Ricerca Corrente 20/1819).

References

  1. Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015;131:269-79. https://doi.org/10.1161/CIRCULATIONAHA.114.010637
  2. Authors/Task Force Members, McDonagh TA, Metra M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
  3. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7-11. https://doi.org/10.15420/cfr.2016:25:2
  4. Tromp J, Khan MAF, Klip IT, et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc 2017;6:472-82. https://doi.org/10.1161/JAHA.116.003989
  5. Aranda JM Jr, Westover MB, Bui AL, et al. Precision medicine in heart failure. JACC Heart Fail 2019;7:263-73.  https://doi.org/10.1016/j.jchf.2019.02.004
  6. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol 2022;19:100-16. https://doi.org/10.1038/s41569-021-00605-5
  7. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022;145:e876-94. https://doi.org/10.1161/CIR.0000000000001073
  8. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Int J Heart Fail 2023;5:66-81. https://doi.org/10.36628/ijhf.2023.0011
  9. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-61. https://doi.org/10.1056/NEJMoa2107038
  10. Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2022;80:1302-10. https://doi.org/10.1016/j.jacc.2022.07.021
  11. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-92. https://doi.org/10.1056/NEJMoa1313731
  12. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67. https://doi.org/10.1056/NEJMoa0805450
  13. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 2014;115:79-96. https://doi.org/10.1161/CIRCRESAHA.115.302922
  14. Savarese G, Uijl A, Ouwerkerk W, et al. Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. ESC Heart Fail 2022;9:2107-18. https://doi.org/10.1002/ehf2.13917
  15. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526-34. https://doi.org/10.1093/eurheartj/ehv728
  16. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. https://doi.org/10.1056/NEJMoa1911303
  17. Packer M. Role of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in the treatment of patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Future Cardiol 2020;16:11-8. 
  18. Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled? Curr Heart Fail Rep 2021;18:315-28. https://doi.org/10.1007/s11897-021-00529-8
  19. Deschaine B, Verma S, Rayatzadeh H. Clinical evidence and proposed mechanisms of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: a class effect? Card Fail Rev 2022;8:e23.
  20. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-targeted heart failure therapy: conceptual framework and practical applications. JACC Heart Fail 2020;8:129-41. 
  21. Swedberg K. Heart failure subtypes: pathophysiology and definitions. Diabetes Res Clin Pract 2021;175:108815.
  22. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263-71.  https://doi.org/10.1016/j.jacc.2013.02.092
  23. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023;118:3434-50. https://doi.org/10.1093/cvr/cvac120
  24. McHugh K, DeVore AD, Wu J, et al. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:602-11. https://doi.org/10.1016/j.jacc.2018.11.033
  25. Joslin JR, Lioudaki E, Androulakis E. Interrelation between heart failure with preserved ejection fraction and renal impairment. Rev Cardiovasc Med 2022;23:69.
  26. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015;46:903-75. https://doi.org/10.1183/13993003.01032-2015
  27. Chan J, Sanderson J, Chan W, et al. Prevalence of sleep-disordered breathing in diastolic heart failure. Chest 1997;111:1488-93. https://doi.org/10.1378/chest.111.6.1488
  28. Pinter A, Behon A, Veres B, et al. The prognostic value of anemia in patients with preserved, mildly reduced and recovered ejection fraction. Diagnostics (Basel) 2022;12:517.
  29. Triposkiadis F, Sarafidis P, Briasoulis A, et al. Hypertensive heart failure. J Clin Med 2023;12:5090.
  30. Aimo A, Senni M, Barison A, et al. Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart Fail Rev 2023;28:179-91. https://doi.org/10.1007/s10741-022-10228-8
  31. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34-42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255
  32. Edelmann F, Musial-Bright L, Gelbrich G, et al. Effect of spironolactone in patients with Heart Failure with Preserved Ejection Fraction (TOPCAT-Americas) based on regional differences. Circ Heart Fail 2020;13:e006520. 
  33. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-20. https://doi.org/10.1056/NEJMoa1908655
  34. Jaarsma T, Hill L, Bayes-Genis A, et al. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23:157-74. https://doi.org/10.1002/ejhf.2008
  35. Obokata M, Reddy YNV, Psaty BM, et al. Independent association of obesity with long-term outcomes in patients hospitalized with heart failure with preserved ejection fraction. JACC Heart Fail 2019;7:827-37. 
  36. Volpe M, Borghi C, Cameli M, et al. How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion. Int J Cardiol 2023;381:101-4. https://doi.org/10.1016/j.ijcard.2023.03.054
  37. Kaplon-Cieslicka A, Benson L, Chioncel O, et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP heart failure long-term registry. Eur J Heart Fail 2022;24:335-50. https://doi.org/10.1002/ejhf.2408
  38. Al-Ozairi E, Irshad M, Taghadom E, et al. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes. Obesity (Silver Spring) 2023;31:716-23. https://doi.org/10.1002/oby.23677
  39. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-84. https://doi.org/10.1056/NEJMoa2306963
  40. Guarini G, Huqi A, Morrone D, Capozza PFG, Marzilli M. Trimetazidine and other metabolic modifiers. Eur Cardiol 2018;13:104-11. https://doi.org/10.15420/ecr.2018.15.2
  41. Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation 2022;146:676-86. https://doi.org/10.1161/CIRCULATIONAHA.122.059785
  42. Sachdev V, Sharma K, Keteyian SJ, et al. Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2023;81:1524-42. https://doi.org/10.1016/j.jacc.2023.02.012
  43. Gorter TM, van Veldhuisen DJ, Mulder BA, et al. Prevalence and incidence of atrial fibrillation in heart failure with mildly reduced or preserved ejection fraction: (additive) value of implantable loop recorders. J Clin Med 2023;12:3682.
  44. Ariyaratnam JP, Elliott AD, Mishima RS, Gallagher C, Lau DH, Sanders P. Heart failure with preserved ejection fraction: an alternative paradigm to explain the clinical implications of atrial fibrillation. Heart Rhythm O2 2021;2:771-83. https://doi.org/10.1016/j.hroo.2021.09.015
  45. Lee KS, Park DI, Lee J, Oh O, Kim N, Nam G. Relationship between comorbidity and health outcomes in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2023;23:498.
  46. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484-92. https://doi.org/10.1161/CIRCULATIONAHA.115.018614
  47. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498. https://doi.org/10.1093/eurheartj/ehaa612
  48. E Darby Md A. Management of atrial fibrillation in patients with heart failure. J Atr Fibrillation 2014;7:1105.
  49. Suzuki S, Kitai T, Skoularigis J, Spiliopoulos K, Xanthopoulos A. Catheter ablation for atrial fibrillation in patients with heart failure: current evidence and future opportunities. J Pers Med 2023;13:1394.
  50. Rangaswami J, Bhalla V, Blair JE, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2019;139:e840-78. https://doi.org/10.1161/CIR.0000000000000664
  51. Masarone D, Martucci ML, Errigo V, Pacileo G. The use of β-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 2021;8:101.
  52. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-70. https://doi.org/10.1093/ehjci/jev014
  53. Dell'Angela L, Nicolosi GL. From ejection fraction, to myocardial strain, and myocardial work in echocardiography: clinical impact and controversies. Echocardiography 2024;41:e15758.
  54. Brown LAE, Wahab A, Ikongo E, et al. Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction. Eur Heart J Cardiovasc Imaging 2022;24:38-45. https://doi.org/10.1093/ehjci/jeac204
  55. Hashemi D, Motzkus L, Blum M, et al. Myocardial deformation assessed among heart failure entities by cardiovascular magnetic resonance imaging. ESC Heart Fail 2021;8:890-7.  https://doi.org/10.1002/ehf2.13193
  56. Bayes-Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail 2023;25:1891-8. https://doi.org/10.1002/ejhf.3036
  57. von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013;6:594-605. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000289
  58. Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 2015;13:78.
  59. Bavishi A, Patel RB. Addressing comorbidities in heart failure: hypertension, atrial fibrillation, and diabetes. Heart Fail Clin 2020;16:441-56. https://doi.org/10.1016/j.hfc.2020.06.005